ClinicalTrials.gg
Not yet recruitingNCT07139353Updated Aug 24, 2025

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

A Phase 1/2 interventional study of Linperlisib and Chidamide in Peripheral T Cells Lymphoma (PTCL), sponsored by Sun Yat-sen University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Sun Yat-sen University · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral — 17 open to participants now, 18 under way, 2 of them phase 3. tucidinostat · Lymphoma, T-Cell, Peripheral.

Planned enrollment
12th of 29
54 · median 44
Started
2025
with 3 others
Phase 1/2
6 of 29
6 open now
Primary completion
2027-09
later than 11 of 17 live
Registered
27th of 29
by date
Lead sponsor
5 of 29
Sun Yat-sen University

Among the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, this one is the 12th largest by planned enrollment, is one of 4 that started in 2025, is one of 6 in phase 1/2, reaches primary completion later than 11 of the 17 other live ones, and was the 27th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

17 of the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral are open now, in 2 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma

03

Conditions studied

  • Peripheral T Cells Lymphoma (PTCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in the clinical study; fully understand and be informed about the study and sign the Form (ICF); willing to comply with and capable of completing all trial procedures;
  • Diagnosed with PTCL according to the 2022 revised WHO lymphoma classification standards based on pathological diagnosis by the research center
  • Using the Lugano 2014 lymphoma efficacy evaluation criteria, the patient must have at least one measurable or evaluable lesion
  • Treatment failure to at least one prior line of systemic standard therapy for PTCL.
  • Age ≥ 18 years
  • Expected survival greater than 12 weeks
  • (ECOG) performance status of 0-2
  • Adequate organ and bone marrow function

Exclusion criteria

Exclusion Criteria:

  • Accompanied by hemophagocytic lymphohistiocytosis (HLH)
  • Lymphoma involvement in the central nervous system or meninges
  • Active infections
  • Uncontrolled clinical cardiac symptoms or diseases
  • Currently using (or unable to stop at least one week prior to the first dose) a known strong inducer or strong inhibitor.
  • Currently using vitamin K antagonists, antiplatelet drugs, anticoagulants (or unable to stop them within one week prior to the start of the study treatment).
  • History of (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
  • Patients with mental disorders or those unable to provide
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Linperlisib Combined with Chidamide

    Patients will receive Chidamide 20 mg orally twice weekly (biw) in combination with Linperlisib at the RP2D (80 mg or 60 mg, po, qd). Each treatment cycle is 28 days.

    Drug: Linperlisib · Drug: Chidamide

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) for Phase 1b

    To identify the DLT

    Time frame: The first cycle (each cycle is 28 days) after administration

  2. Overall response rate(ORR) for Phase 2

    The proportion of patients who achieve complete remission (CR) or partial remission (PR) as the best response.

    Time frame: Up to 24 months

Secondary outcomes

  1. Complete response rate (CRR)

    Defined as the proportion of patients who achieve complete remission as the best response

    Time frame: Up to 24 months

  2. Duration of Response(DOR)

    To investigate the preliminary anti-tumor efficacy

    Time frame: Up to 4 years

  3. Progression-free survival(PFS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: Up to 4 years

  4. Overall survival(OS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: Up to 4 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2027, 23 months later.

Of 31 phase 1/2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 65. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 24, 2025
StartEst.
Sep 15, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2029
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07139353
Responsible party
Qingqing Cai (MD. PhD., Sun Yat-sen University) — Principal investigator
First posted
Aug 24, 2025
Start date
Sep 15, 2025 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Aug 24, 2025

Study contacts

Qingqing Cai
Contact
caiqq@sysucc.org.cn
+862087342823

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linperlisib · Tucidinostat

Start the discussion